FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking ...

FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

(RTTNews) - PDS Biotech (PDSB), a late-stage immunotherapy company focused on cancer treatments, announced Thursday that the U.S. Food and Drug Administration or FDA has cleared its Investigational ...

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a ...

SHENZHEN, China, May 28, 2025 /PRNewswire/ -- On May 26th, Kexing Biopharm (688136.SH) announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND ...

In August 2024, Bin Xia Yang, a portfolio director at the pharmaceutical company Axcynsis Therapeutics, geared up to move the company’s new tumor-fighting antibody-drug conjugate into clinical trials.

Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...

ILKN421H is a novel lipid nanoparticle (LNP)-formulated mRNA encoding a non-alpha HSA–IL-2v fusion protein and dominantly expressed in lymphoid organs after IV injection. ILKN421H selectively expanded ...

Silo Pharma, Inc. announced plans to submit an investigational new drug (IND) application for SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD), by the end of 2025, ...